Timothy Marler and Daniel M. Gerstein

Biotechnology has a broad and often misunderstood scope, one with significant implications for today's warfighter. In many respects, biotechnology—and the bioeconomy more broadly—is still an emerging field, and this can exacerbate the already limited understanding of their scope. Despite a 2020 National Academies of Sciences, Engineering, and Medicine study that characterized the bioeconomy (PDF) as more than five percent of the U.S. gross domestic product (or $959.2 billion) in 2016, it is relatively young and often ill defined. It may have far greater potential than even these impressive totals would suggest. Furthermore, just as the technology is emerging, so too are the definitions that govern these areas. Fundamentally, however, biotechnology involves the manipulation of living organisms or their components to produce useful products. Meanwhile, the broader term, bioeconomy, is based on products, services, and processes derived from biological resources (PDF).
In addition to an unclear definition, public awareness (PDF), understanding, and acceptance (PDF) of biotechnology may sometimes be insufficient, and this presents yet another confounding factor. It makes gaining attention for these issues and developing proactive policies challenging. Policymakers may also underestimate what biotechnology entails or how important it can be. Yet, the field can provide a wide range of opportunities to the United States while also presenting challenges and risks. Mitigating these risks and capitalizing on the opportunities could provide substantial competitive advantages for the United States—but only if we better understand what biotechnology is.





















